Novel microsomal triglyceride transfer protein inhibitors

Bibliography

• CONNOR SL, GUSTAFSON JR, ARTAUD-WILD SM et al.: The cholesterol/saturated-fat index: an indication of the hypercholesterolaemic and atherogenic potential of food. Lancet (1986) 1(8492):1229–1232.
   PubMedGoogle Scholar
• AUSTIN MA, HOKANSON JE, EDWARDS KL: Hypertriglyceridemia as a cardiovascular risk factor. Am." Cardiol. (1998) 81(447B–12B.
   Google Scholar
• ASSMANN G, SCHULTE H: Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster study. Am. J. Cardiol. (1992) 70(19):10H-13H.
   Google Scholar
• SCHAEFER EJ, LEVY RI: Pathogenesis and management of lipoprotein disorders. N. Engl. J. Med. (1985) 312:1300–1310.
   PubMed Web of Science ®Google Scholar
• ILLINGWORTH DR Lipoprotein metabolism. Am. "Kidney Dir. (1993) 22:90–97.
   Google Scholar
• YOUNG SG: Recent progress in understanding apolipoprotein B. Circulation(1990) 82:1574–1594.
   PubMed Web of Science ®Google Scholar
• UTERMANN G: The mysteries of lipoprotein (a). Science (1989) 246:904–910.
   PubMed Web of Science ®Google Scholar
• KNIGHT BL: Lp(a) catabolism in hypercholesterolaemic individuals. Chem. Phys. Lipids(1994) 67–68:233–239.
   Google Scholar
• WILSON PW, DAGOSTINO RB, LEVY D, BELANGER AM, SILBERSHATZ H, KANNEL WB: Prediction of coronary heart disease using risk factor categories. Circulation (1998) 97:1837–1847.
   PubMed Web of Science ®Google Scholar
• TOLLESHAUG H, HOBGOOD KK, BROWN MS, GOLDSTEIN JL: The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor. Cell (1983)32:941–951.
   PubMedGoogle Scholar
• KOSTNER KM, KOSTNER GM: Lipoprotein(a): still an enigma. Carr: Opin. Lipidol. (2002) 13:391–396.
   PubMed Web of Science ®Google Scholar
• KRAUSS RIVI: Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. (1998) 81(4413B–17B.
   Google Scholar
• GOLDSTEIN JL, SCHROTT HG, HAZZARD WR, BIERMAN EL, MOTULSKY AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. Clin. Invest. (1973) 52:1544–1568.
   Google Scholar
• VENKATESAN S, CULLEN P, PACY P, HALLIDAY D, SCOTT J: Stable isotopes show a direct relation between VLDL ApoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arteriosclec Thromb. (1993) 13:1110–1118.
   PubMedGoogle Scholar
• KWITEROVICH PO: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am." Cardiol (2002) 90(8430i–47i.
   Google Scholar
• RUOTOLO G, HOWARD BV: Dyslipidemia of the metabolic syndrome. Carr. Cardiol. Rep. (2002) 4:494–500.
   PubMedGoogle Scholar
• GENEST J, NGUYEN NH, THEROUX P, DAVIGNON J, COHN JS: Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J. Cardiovasc. Pharmacol. (2000) 35:164–172.
   PubMed Web of Science ®Google Scholar
• GORDON DA, JAMIL H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta (2000) 1486:72–83.
   PubMed Web of Science ®Google Scholar
• •Reviews role of MTP in chylomicron and VLDL assembly.
   Google Scholar
• LEVY E, STAN S, DELVIN E et al.: Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J. Biol. Chem. (2002) 277:16470–16477.
   PubMed Web of Science ®Google Scholar
• LIANG J, GINSBERG HN: Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells. Biol. Chem. (2001) 276:28606–28612.
   Google Scholar
• WETTERAU JR, LIN MCM, JAMIL H: Microsomal triglyceride transfer protein. Biochim. Biophys. Acta. (1997) 1345:136–150.
   PubMedGoogle Scholar
• WETTERAU JR, COMBS KA, SPINNER SN, JOINER BJ: Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J. Biol. Chem. (1990) 265:9801–9807.
   Google Scholar
• DASHTI N, GANDHI M, LIU X, SEGREST JP: The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry (2002) 41:6978–6987.
   PubMed Web of Science ®Google Scholar
• •Explains how MTP attaches triglyceride to ApoB.
   Google Scholar
• SHELNESS GS, SELLERS JA: Very-low-density lipoprotein assembly and secretion. Can: Opin. Lipidol. (2001) 12:151–157.
   PubMed Web of Science ®Google Scholar
• HAGAN DL, KIENZLE B, JAMIL H, HARIHARAN N: Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J. Biol. Chem. (1994) 269:28737–28744.
   Google Scholar
• RAABE M, FLYNN LM, ZLOT CH et al.:Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Nati Acad. Sci. USA (1998) 95:8686–8691.
   PubMed Web of Science ®Google Scholar
• WETTERAU JR, AGGERBECK LP, BOUMA ME et al.: Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science (1992) 258:999–1001.
   PubMed Web of Science ®Google Scholar
• RADER DJ, BREWER HB Jr: Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA (1993) 270:865–869.
   PubMed Web of Science ®Google Scholar
• KARPE F, LUNDAHL B, EHRENBORG E, ERIKSSON P, HAMSTEN A: A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler. Thromb. Vasc. Biol. (1998) 18:756–761.
   PubMed Web of Science ®Google Scholar
• JAMIL H, GORDON DA, EUSTICE DC et al.: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl. Acad. Sci. USA (1996) 93:11991–11995.
   PubMed Web of Science ®Google Scholar
• ••Early MTP inhibitor, from which manyothers have been derived. Describes cell-based assays of activity.
   Google Scholar
• ARROL S, MACKNESS MI, DURRINGTON PN: The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis (2000) 150:255–264.
   PubMedGoogle Scholar
• BAKILLAH A, NAYAK N, MEDFORD PM, HUSSAIN MM: Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry (2000) 39:4892–4899.
   PubMed Web of Science ®Google Scholar
• CARDOZO C, WU X, PAN M, WANG H, FISHER EA: The inhibition of microsomal triglyceride transfer protein activity in hepatoma cells promotes proteasomal and non-proteasomal degradation of apoprotein B100. Biochemistry (2002) 41:10105–10114.
   PubMedGoogle Scholar
• CHANG G, RUGGERI RB, HARWOOD HJ: Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Can: Opin. Drug Discov. Devel. (2002) 5:562–570.
   PubMed Web of Science ®Google Scholar
• •Recent review of the discovery process of MTP inhibitors.
   Google Scholar
• WETTERAU JR, GREGG RE, HARRITY TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751–754.
   PubMed Web of Science ®Google Scholar
• •MTP inhibitor normalises LDL-cholesterol in animal model of familial hypercholesterolaemia.
   Google Scholar
• ROBL JA, SULSKY R, SUN CQ et al: A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. I Med. Chem. (2001) 44:851–856.
   PubMed Web of Science ®Google Scholar
• KSANDER GM, DEJESUS R, YUAN A et al.: Diaminoindanes as microsomal triglyceride transfer protein inhibitors. Med. Chem. (2001) 44:4677–4687.
   Google Scholar
• LIAO W, HUI TY, YOUNG SG, DAVIS R: Blocking microsomal triglyceride transfer protein interferes with apolipoprotein B secretion without causing retention or stress in the endoplasmic reticulum. I Lipid Res. (2003) [Electronically published ahead of print].
   Google Scholar
• SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Ear: Pharmacol. (2001) 431:127–131.
   PubMed Web of Science ®Google Scholar
• WETTERAU JR, ZILVERSMIT DB: Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim. Biophys. Acta (1986) 875:610–617.
   PubMed Web of Science ®Google Scholar
• NIELSEN LB, VENIANT M, BOREN J et al.: Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation (1998) 98:13–16.
   PubMed Web of Science ®Google Scholar
• GOTTO AM: Risk factor modification: rationale for management of dyslipidemia. Am. Med. (1998) 104(2465–85.
   Google Scholar
• CROUSE JR: Effects of statins on carotid disease and stroke. Curt: Opin. Lipidol. (1999) 10:535–541.
   PubMedGoogle Scholar
• CHAPMAN MJ, CASLAKE M, PACKARD C, MCTAGGART F: New dimension of statin action on Apo B atherogenicity. Clin. Cardiol. (2003) 26\(Supp1.1):I7410.
   Google Scholar
• CHAN DC, WATTS GE REDGRAVE TG, MORI TA, BARRETT PH: Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism (2002) 51:1041–1046.
   PubMed Web of Science ®Google Scholar
• •Overproduction of VLDL particles in central obesity could be treated with an MTP inhibitor.
   Google Scholar
• GINSBERG HN, ILLINGWORTH DR: Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am. Cardiol. (2001) 88(6A):9H–15H.
   Google Scholar
• BJORKEGREN J, BEIGNEUX A, BERGO MO, MAHER JJ, YOUNG SG: Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J. Biol. Chem. (2002) 277:5476–5483.
   PubMed Web of Science ®Google Scholar
• BJORKEGREN J, VENIANT M, KIM SK et al.: Lipoprotein secretion and triglyceride stores in the heart. J. Biol. Chem. (2001) 276:38511–38517.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar